Showing results (231-240 of 253) with videos related to
Sort By:
Pageof 26
Clinical Immunology (Orlando, Fla.)|January 24, 2021
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancerR Connor Chick, G Travis Clifton, Diane F Hale, et al.Annals of Surgical Oncology|June 28, 2019
Inpatient Opioid Use After Pancreatectomy: Opportunities for Reducing Initial Opioid Exposure in Cancer Surgery PatientsTimothy E Newhook, Whitney L Dewhurst, Timothy J Vreeland, et al.Journal of Extracellular Vesicles|April 14, 2021
Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal single-particle analysis platformsTanina Arab, Emily R Mallick, Yiyao Huang, et al.Cancer Medicine|July 6, 2019
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patientsTommy A Brown, Kevin Byrd, Timothy J Vreeland, et al.Annals of Surgical Oncology|February 28, 2021
A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary AnalysisTimothy J Vreeland, Guy T Clifton, Diane F Hale, et al.Annals of Surgery|June 11, 2025
First National Effort to Optimize the Performance of Cancer Surgery by the American College of Surgeons Commission on Cancer and Cancer Surgery Standards Program: Early Results After Implementation of the Operative StandardsMatthew H G Katz, Amanda B Francescatti, Timothy W Mullett, et al.Journal of Surgical Oncology|October 6, 2023
Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing mattersFranklin A Valdera, Anne E O'Shea, Todd R Smolinsky, et al.Annals of Surgery|January 17, 2023
Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic AdenocarcinomaTimothy E Newhook, Timothy J Vreeland, James F Griffin, et al.Oncotarget|November 17, 2016
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patientsDoreen O Jackson, Kevin Byrd, Timothy J Vreeland, et al.Melanoma Research|July 1, 2021
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanomaAlexandra M Adams, Robert C Chick, Timothy J Vreeland, et al.Pageof 26